IMMUNIQUE
IMMUNIQUE Inc. is a company specialized in the development of cord blood-derived immune cell therapeutics. Our focus centres on developing regulatory T cell therapeutics to treat intractable diseases including autoimmune diseases and immunodeficiency related diseases.
With over 24 years of experience in cord blood-related basic and clinical research, along with the commercialization expertise of our parent company, MEDIPOST, in stem cell therapeutics, IMMUNIQUE is ready to leap forward as a company specialized in immune cell therapeutics.
- For more information, visit: www.immunique.co.kr
MEDIPOST
MEDIPOST CO., LTD (KOSDAQ 078160) is leading the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell (hUCB-MSC) product named CARTISTEM® for patients with knee osteoarthritis (OA), launched in the Korean market in 2012.
Through many years of research on characterization of cord blood-derived stem cells, MEDIPOST’s R&D Institute has been focusing on revealing the cord blood-derived stem cells’ therapeutic effects by understanding their therapeutic mechanisms. Additionally, various routes of cell administration and methods for improving cell manufacturing have been developed by MEDIPOST.
MEDIPOST is headquartered in South Korea, with its wholly-owned subsidiaries in the U.S. (MEDIPOST Inc.) and Japan (EVASTEM Co., Ltd.), as well as a stake-holding at a CDMO in Ontario (OmniaBio Inc.), Canada.
For more information, visit: www.medi-post.co.kr
